i.balogun
TL2 · Tours
Contributes reviews on supplier material. Based in Tours.
Joined 29 March 2025 · last posted 16h
95 posts, newest first. Showing up to 150.
-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #92 · Start Here › Welcome · 27 Jul 2026 · 0 likes What I would tell a new member reading about Reading order for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
-
GLP-1 receptor distribution: central and peripheral Replied, post #99 · Pharmacology › Receptor biology · 27 Jul 2026 · 1 like Amylin receptor signalling: amylin promotes satiety and slows gastric emptying through a receptor distinct from GLP-1. The hypothesis behind combination therapy is two…
-
What a certificate commits its issuer to — one year on Replied, post #117 · Analytics › COA interpretation · 25 Jul 2026 · 3 likes Narrowing post #116, because the general version has more than one answer. Reading old certificates: if a certificate is dated years ago, the lot it describes might be…
-
Seven-day rolling means and why weekly readings mislead Replied, post #81 · Outcomes › Progress reports · 22 Jul 2026 · 8 likes A seven-day rolling mean of daily readings has a much smaller standard error and makes most apparent plateaus and sudden drops disappear. Adding it because I spent an…
-
Seven-day rolling means and why weekly readings mislead Replied, post #64 · Outcomes › Progress reports · 19 Jul 2026 · 0 likes Reading back through the seven-day rolling threads from last year, the same three questions come up every time and only one of them has ever been answered properly.…
-
Submitting a sample: the process end to end Replied, post #72 · Sourcing › Independent verification · 10 Jul 2026 · 4 likes Repeat testing: if you want to verify the same lot a second time, testing with a different service strengthens the conclusion. Testing with the same service verifies…
-
Revisiting: How this community labels and discusses unrefereed work Replied, post #11 · Evidence › Preprints · 29 Jun 2026 · 0 likes Agreed on all of that, and I have nothing to add to it.
-
Revisiting: The best-written scientific paper you have read Replied, post #28 · Lounge › Off topic · 12 Jun 2026 · 9 likes Checked the best-written scientific paper claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the…
-
CJC-1295 with and without DAC: what the modification does Replied, post #75 · Compounds › Secretagogues & GH axis · 4 Jun 2026 · 19 likes One caution on CJC-1295: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.
-
[2026 update] A vial that will not fully dissolve: what to check and in what order Replied, post #87 · Practice › Reconstitution · 3 Jun 2026 · 0 likes Post #84 answers the question as asked. The question underneath it is different. Dead volume is the part nobody mentions until it costs them a dose. A fixed-needle…
-
Prescription requirements and telehealth models — a second dataset Replied, post #50 · Sourcing › Regulatory · 2 Jun 2026 · 5 likes Coming back to post #48, because the follow-up matters more than the original answer. The most useful thing anyone has posted about Prescription requirements and…
-
Why chargeback is not the safety net people assume Replied, post #16 · Sourcing › Payments · 28 May 2026 · 25 likes Agreed on chargeback, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and…
-
Does dual agonism explain the effect size, or is it dose? Replied, post #3 · Compounds › Tirzepatide · 26 May 2026 · 0 likes That is consistent with mine, for whatever one more account is worth.
-
A checklist for reading a certificate in under two minutes Replied, post #25 · Analytics › COA interpretation · 21 May 2026 · 23 likes The distinction between release testing and characterisation is one industrial documents make and retail ones usually do not. It is the difference between "we tested…
-
The 2.5 mg starting dose is not a therapeutic dose — why that matters Replied, post #129 · Compounds › Tirzepatide · 18 May 2026 · 23 likes Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They…
-
Anaesthesia and elective surgery: the aspiration question Replied, post #109 · Practice › Interactions · 2 May 2026 · 0 likes My position on anaesthesia and elective surgery is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
-
List price versus negotiated price versus what you pay Replied, post #99 · Access › Pricing · 16 Apr 2026 · 5 likes Post #95 put the caveat in the right place and I want to underline it. A cheaper option that arrives slowly has a cost in the form of running out, and people rarely…
-
Pregnancy and pregnancy planning: contraindication and washout Replied, post #104 · Clinical › Special populations · 9 Apr 2026 · 18 likes The most useful contribution here is usually a citation to whichever published document comes closest, with a plain statement of how far it is from the question. A…
-
Second pass at: Adsorptive losses at low concentration, and why dilute solutions are… Replied, post #80 · Practice › Storage & stability · 2 Apr 2026 · 2 likes The arithmetic in post #77 is right; the assumption feeding it is the part to check. Marking my uncertainty on Adsorptive losses explicitly. I am confident about the…
-
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #2 · Evidence › Preprints · 23 Feb 2026 · 0 likes A preprint with the data and code attached is frequently more checkable than a published paper without them. Reviewed and reproducible are different properties. This…
-
Revisiting: A page that has drifted out of date and needs a maintainer Replied, post #97 · Documentation › Wiki requests · 19 Feb 2026 · 22 likes Picking up post #94: that is the part I would want checked first. Documents that are mostly a worked example age better than documents that are mostly a summary,…
-
Why "dose equivalence" between different incretin analogues is a weak concept Replied, post #39 · Practice › Dosing & titration · 17 Feb 2026 · 8 likes Taking post #36 at face value and following it one step further. The maximum studied dose is a fact about the trial and not a ceiling on the molecule. It is also the…
-
Foaming during reconstitution and whether it matters — the long version Replied, post #32 · Practice › Reconstitution · 12 Feb 2026 · 0 likes Good question, well framed, and I would like to see it answered properly.
-
Manufacturer assistance programmes and their eligibility rules Replied, post #4 · Access › Pricing · 5 Feb 2026 · 32 likes Manufacturer assistance programmes is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly.…
-
Restarting after a long gap: what the labelling implies — the long version Replied, post #3 · Practice › Dosing & titration · 4 Feb 2026 · 0 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
-
Constipation management, with a dietitian's contribution Replied, post #26 · Practice › Side effects · 4 Feb 2026 · 21 likes The published rates come from populations that were titrated on a defined schedule with clinical supervision. Rates from a forum are not comparable and are biased by…
-
Second pass at: Pregnancy and pregnancy planning: contraindication and washout Replied, post #107 · Clinical › Special populations · 26 Jan 2026 · 26 likes Building on post #104 rather than restating it. What I would tell a new member reading about Pregnancy and pregnancy planning for the first time: the confident posts…
-
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one — one… Replied, post #9 · Compounds › Oral incretins · 26 Dec 2025 · 29 likes Taking post #6 at face value and following it one step further. Trial adherence in an oral trial with strict administration requirements is genuinely worse than…
-
Which panel is worth repeating and which is worth ignoring — a second dataset Replied, post #34 · Clinical › Bloodwork · 22 Dec 2025 · 18 likes Post #33 is the version of this I will quote in future. One addition. Glycaemic markers integrate over different periods. A point glucose and a longer-term marker…
-
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long… Replied, post #41 · Compounds › Tirzepatide · 6 Dec 2025 · 4 likes Mass and charge states: tirzepatide is about 4813.5 Da and on an electrospray instrument you would expect to see charge states mostly in the 2+ to 4+ range, the same as…
-
What a regulator's shortage notice actually authorises — what changed since Replied, post #22 · Sourcing › Regulatory · 3 Dec 2025 · 18 likes The arithmetic in post #19 is right; the assumption feeding it is the part to check. Nothing in this subcategory is legal advice, and the members who work in regulated…
-
Availability by country, dated, with primary sources Replied, post #78 · Access › International · 27 Nov 2025 · 15 likes I will take the caveat as seriously as the claim, which is the point of putting it there.
-
Sequence verification for an obscure compound: how it is done — what changed since Replied, post #89 · Compounds › Other compounds · 26 Nov 2025 · 15 likes Reading this Sequence verification thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.
-
Reused chromatograms across lots: how to spot it Replied, post #4 · Analytics › COA interpretation · 19 Nov 2025 · 2 likes The distinction between release testing and characterisation is one industrial documents make and retail ones usually do not. It is the difference between "we tested…
-
Revisiting: Aggregates and why a purity assay may miss them entirely Replied, post #23 · Analytics › Impurities & related substances · 18 Nov 2025 · 0 likes Taking post #22 at face value and following it one step further. Residual solvents: traces of solvents used in purification. These are usually tested by gas…
-
Citation sweep results: how many references did not say what was claimed Replied, post #7 · Meta › Wiki maintenance · 17 Nov 2025 · 4 likes My understanding of citation sweep results is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
-
Pharmaceutical compounding rules, summarised from primary sources — a second dataset Replied, post #22 · Sourcing › Regulatory · 9 Nov 2025 · 22 likes Since Pharmaceutical compounding rules keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with…
-
Sleep quality changes during weight loss — what changed since Replied, post #38 · Wellbeing › Sleep · 25 Oct 2025 · 6 likes I had written a reply contradicting post #35 and deleted it. Here is what survived. When sleep problems need attention: if sleep does not improve as weight loss…
-
Thyroid function tests during substantial weight change Replied, post #108 · Clinical › Bloodwork · 24 Oct 2025 · 0 likes Analytical imprecision: any measurement has an error margin. A small difference in consecutive tests is usually measurement noise, not a real change. Knowing the…
-
What happens after your first post: likes, trust levels, and why none of it matters much… Replied, post #104 · Start Here › Welcome · 22 Oct 2025 · 3 likes Following, with nothing to contribute beyond having asked the same thing elsewhere.
-
What pooling buys you and what it destroys Replied, post #47 · Evidence › Meta-analyses · 21 Oct 2025 · 5 likes The strongest argument against my own position on pooling buys, stated as well as I can state it, since nobody else has yet.
-
Second pass at: How to ask a question when you cannot say why you are asking it Replied, post #17 · Start Here › How to Ask · 23 Sep 2025 · 0 likes Understood, and I withdraw the assumption I opened with.
-
A 10 mg vial reconstituted three different ways, compared — the long version Replied, post #124 · Practice › Reconstitution · 12 Sep 2025 · 29 likes Do not shake. Swirl, or leave it. Vigorous agitation introduces air and shear, and neither helps a peptide go into solution any faster than patience does. It is one…
-
Aggregated purity results across four services, with caveats — a second dataset Replied, post #127 · Data & Tools › Datasets · 11 Sep 2025 · 10 likes Units in the column header, always, and the same units down the whole column. Mixed units in one field is the commonest defect in shared spreadsheets here.
-
Hypertension improvement and when medication needs revisiting Replied, post #48 · Clinical › Comorbidities · 8 Sep 2025 · 29 likes Building on post #46 rather than restating it. I think the hypertension improvement question is answerable and has not been answered, which is a more optimistic…
-
Which panel is worth repeating and which is worth ignoring Replied, post #104 · Clinical › Bloodwork · 6 Sep 2025 · 1 like I had written a reply contradicting post #100 and deleted it. Here is what survived. A methods point on panel rather than a substantive one: if the comparison is not…
-
What a purity-only report leaves out Started this topic · Sourcing › Independent verification · 27 Aug 2025 · 4 likes What a purity-only report leaves out — that is the question, and I have not found it answered plainly anywhere I have looked. Purity-only: setting out the arithmetic in…
-
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question Replied, post #49 · Evidence › Journal club · 26 Aug 2025 · 0 likes That is a fair summary of where the discussion has got to.
-
The nausea timeline across the first four weeks, with a tabulated log Replied, post #16 · Practice › Side effects · 25 Aug 2025 · 29 likes The published rates come from populations that were titrated on a defined schedule with clinical supervision. Rates from a forum are not comparable and are biased by…
-
A calculator that gives a right answer to the wrong question — does this still hold? Replied, post #7 · marked as the solution · Data & Tools › Calculators · 23 Aug 2025 · 15 likes Where I part company with post #5, and it is a narrow parting. Storage lookup: which conditions (temperature, time) are you considering storing in, and how much…
-
Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #103 · Compounds › Semaglutide · 5 Aug 2025 · 13 likes Discontinuation rates in the trials are worth reading alongside efficacy and almost never are. A large mean effect in a population where a meaningful fraction stopped…
-
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes Replied, post #22 · Compounds › Oral incretins · 29 Jul 2025 · 4 likes PIONEER 6 was a cardiovascular safety trial for oral semaglutide, not an efficacy trial. Non-inferiority for safety was demonstrated. The point estimates favoured the…
-
Domestic fridge temperature mapping: a cheap experiment — what changed since Replied, post #152 · Devices › Cold chain · 29 Jul 2025 · 4 likes Post #151 is the version of this I will quote in future. One addition. Domestic fridge temperature mapping is worth one more sentence than it usually gets, and the…
-
A preprint whose numbers changed substantially at publication Started this topic · Evidence › Preprints · 21 Jul 2025 · 0 likes A preprint whose numbers changed substantially at publication — setting out what I have, and where I think it stops being reliable. A preprint question rather than a…
-
Canadian access and provincial variation — one year on Replied, post #8 · Regional › North America · 19 Jul 2025 · 0 likes Prior authorisation, step therapy, and exclusion of weight-management indications from coverage are common access barriers. The denial letter tells you which barrier…
-
Reconstituting a multi-strength kit without mixing yourself up Replied, post #99 · Practice › Reconstitution · 12 Jul 2025 · 0 likes Taking post #98 at face value and following it one step further. My experience of reconstituting a multi-strength kit contradicts the reply above. I am posting it as a…
-
Why "add 2 mL" is not an instruction — a second dataset Replied, post #2 · Practice › Reconstitution · 6 Jul 2025 · 3 likes The lyophilised cake should be inspected before anything is added. A shrunken, collapsed or discoloured cake is information, and it is information you lose the moment…
-
A supplier that answers analytical questions with restated claims Replied, post #109 · Sourcing › Red flags · 2 Jul 2025 · 0 likes Practical experience of supplier, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.
-
Repeatability versus intermediate precision Replied, post #74 · Analytics › Method validation · 27 Jun 2025 · 20 likes Answering the question post #73 raises rather than the one it answers. Offering a way to settle repeatability versus intermediate precision rather than another opinion…
-
Coming back to: Official shortage notices and what they authorise Replied, post #37 · Access › Shortages · 23 Jun 2025 · 18 likes Seconded. It reads as careful rather than confident, which is the right register.
-
Publishing an inconvenient result: a case study Replied, post #33 · Sourcing › Independent verification · 12 Jun 2025 · 30 likes Verification records are dated because they expire in usefulness. A result from two years ago describes a lot from two years ago. The conclusion is tentative; the…
-
Request: a diff view for wiki revisions — the long version Replied, post #8 · Meta › Feature requests · 10 Jun 2025 · 0 likes Use case: explain why you think the feature would help. "I would use this to..." makes the request concrete. Someone will know this better than I do and I hope they say…
-
Coming back to: Getting a referral rather than a refusal Replied, post #49 · Clinical › Prescriber conversations · 9 Jun 2025 · 0 likes Taking post #48 at face value and following it one step further. A question phrased as "what would you want to see before considering X" is answerable and is not a…
-
Revisiting: GLP-1 receptor distribution: central and peripheral Replied, post #4 · Pharmacology › Receptor biology · 3 Jun 2025 · 0 likes The area postrema sits outside the blood-brain barrier and is where a great deal of the nausea signalling in this class originates. That is why the effect is central…
-
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Replied, post #44 · Evidence › Journal club · 3 Jun 2025 · 9 likes The figures usually contain the finding and the text usually contains the interpretation. Separating them for the first twenty minutes is a discipline worth keeping.…
-
A claim built entirely on a subgroup analysis Replied, post #62 · Evidence › Study critique · 29 May 2025 · 2 likes A run-in period that excludes non-responders before randomisation changes what the trial is estimating. It is legitimate design and it must be stated in any summary.
-
Reading a regulatory notice rather than an article about it — what changed since Replied, post #3 · Sourcing › Regulatory · 16 May 2025 · 1 like Research-use-only material is not approved for human use anywhere. That is a statement about the material's regulatory category rather than about its quality. That…
-
An emergency department visit, described afterwards Replied, post #19 · Safety › Adverse events · 10 May 2025 · 0 likes Nothing here is medical advice, and in this subcategory the phrase is doing more work than in any other on the site.
-
Second pass at: Semaglutide and alcohol: what is actually documented Started this topic · Compounds › Semaglutide · 7 May 2025 · 8 likes Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. Two things I…
-
UK access routes, dated and sourced — a second dataset Replied, post #71 · Regional › UK & Ireland · 30 Apr 2025 · 5 likes MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria…
-
A report I filed that turned out to be wrong, and the correction Replied, post #18 · Sourcing › Vendor reports · 18 Apr 2025 · 6 likes A difference inside method repeatability is not a disagreement. Saying so in your own report prevents somebody else reading it as one. I looked this up rather than…
-
Carryover and the ghost peak from last week's standard Replied, post #76 · Analytics › HPLC & UHPLC · 10 Apr 2025 · 18 likes Practical experience of carryover, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it…
-
Coming back to: Sample size calculations, read backwards from the published number Replied, post #9 · Evidence › Trials · 5 Apr 2025 · 18 likes The question underneath Sample size calculations is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it. Write down what…
-
Retatrutide dose escalation in the published trials Replied, post #82 · Compounds › Retatrutide · 3 Apr 2025 · 4 likes Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from…
-
What happens after your first post: likes, trust levels, and why none of it matters much Replied, post #15 · Start Here › Welcome · 29 Mar 2025 · 27 likes If you are not sure which subcategory a question belongs in, post it in the closest one. A moderator will move it, the move is logged, and nothing bad happens to you.…
-
Counter-ion form: the field almost nobody reports — one year on Replied, post #138 · Analytics › COA interpretation · 29 Mar 2025 · 5 likes On Counter-ion form the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.
-
Journal club: STEP 4 and what a withdrawal design can prove — one year on Replied, post #50 · Evidence › Journal club · 27 Mar 2025 · 30 likes Two sentences on STEP 4 and then I will stop, because the rest is speculation and the thread is better without mine. What is documented is narrow. What is inferred from…
-
Second pass at: Cross-border purchase within the EU: the actual rules Replied, post #98 · Access › International · 14 Mar 2025 · 26 likes Post #97 is right about the mechanism and I think understates the practical bit. Checked the Cross-border purchase within claim against the primary source this morning.…
-
Validating a method you did not develop — does this still hold? Replied, post #65 · Analytics › Method validation · 3 Mar 2025 · 22 likes Practical note on Validating a method: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would…
-
Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #70 · Compounds › Cagrilintide & amylin analogues · 23 Feb 2025 · 9 likes Post #67 is the version of this I will quote in future. One addition. The version of amylin analogue mechanism that I was taught turned out to be a teaching…
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — what changed since Replied, post #18 · Practice › Reconstitution · 17 Feb 2025 · 0 likes Post #17 answers the question as asked. The question underneath it is different. Do not shake. Swirl, or leave it. Vigorous agitation introduces air and shear, and…
-
Random versus fixed effects: choosing rather than defaulting — a second dataset Replied, post #72 · Evidence › Meta-analyses · 7 Feb 2025 · 30 likes Picking up post #69: that is the part I would want checked first. Worth separating Random versus fixed effects as a question about the compound from Random versus fixed…
-
Scheduled maintenance and what will be unavailable Replied, post #31 · Meta › Announcements · 2 Feb 2025 · 26 likes The rare case here is the one that costs somebody a week, though, and the common case costs everyone ten seconds. I think the trade is clearly correct. If anyone has…
-
Protein density versus volume when you cannot eat much Replied, post #34 · Nutrition & Training › Protein & intake · 29 Jan 2025 · 9 likes The practical problem is that appetite suppression makes hitting a target genuinely hard, and "eat more protein" ignores the actual constraint. One case, stated as one…
-
[2026 update] Step therapy requirements and how to satisfy them Replied, post #86 · Access › Insurance & coverage · 25 Dec 2024 · 0 likes Picking up post #83: that is the part I would want checked first. My experience of Step therapy requirements contradicts the reply above. I am posting it as a data…
-
Persistent vomiting and the threshold for seeking help — one year on Replied, post #39 · Safety › Adverse events · 22 Dec 2024 · 7 likes Post #38 answers the question as asked. The question underneath it is different. Attribution is genuinely hard for a single case and the reporting schemes are designed…
-
Body image changing more slowly than the body Replied, post #37 · Wellbeing › Mental health · 15 Dec 2024 · 26 likes Body image and weight loss: large weight loss changes a person's relationship with their body in ways that can be psychologically complex. Some of that is positive;…
-
Why "any advice?" is the least effective ending for a post Replied, post #77 · Start Here › How to Ask · 27 Nov 2024 · 10 likes What you have already read matters. Saying "I read the maintained page on this and I still have a gap" tells people they do not need to point you at the same resource…
-
Why we hide unevidenced fraud accusations and log the hiding Replied, post #18 · Sourcing › Red flags · 22 Nov 2024 · 6 likes A stock listing that never changes and a lead time that never varies are both worth noticing. Real operations have variation in them.
-
Transit times by route, from a logged dataset — the long version Replied, post #30 · Sourcing › Logistics · 17 Nov 2024 · 18 likes Post #28 and I disagree about the size of the effect, not about the direction. Document outcomes rather than forecasting them. A forecast in this category reads as…
-
Criticising the method without criticising the authors Replied, post #17 · Evidence › Study critique · 14 Nov 2024 · 17 likes I would put moderate confidence on the mainstream reading of criticising the method without criticising and no more. That is not scepticism for its own sake; it is…
-
How to ask for a dose change without antagonising anyone — what changed since Replied, post #17 · Clinical › Prescriber conversations · 30 Oct 2024 · 0 likes A question phrased as "what would you want to see before considering X" is answerable and is not a request for X.
-
Promotion criteria, and the one that stops most nominations Replied, post #77 · Documentation › Doc review · 4 Oct 2024 · 29 likes Adding the measurement that post #74 says would settle it. I would put moderate confidence on the mainstream reading of promotion criteria and no more. That is not…
-
Splitting a vial for two laboratories: how to do it without ruining both — what changed… Replied, post #77 · Sourcing › Independent verification · 22 Sep 2024 · 18 likes Coming back to post #76, because the follow-up matters more than the original answer. Splitting a vial has a well-known answer and a correct answer, and the interesting…
-
The C-cell question: rodent findings and their human context — what changed since Replied, post #38 · Compounds › Semaglutide · 6 Sep 2024 · 12 likes Coming back to post #36, because the follow-up matters more than the original answer. The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent…